
News|Articles|January 2, 2026
Top 5 skin cancer articles of 2025
Author(s)MHE Staff
Listen
0:00 / 0:00
Key Takeaways
- Blood or marrow transplant recipients face higher skin cancer risk due to monoclonal antibody treatment, chronic graft-versus-host disease, and post-transplant immunosuppression.
- AI shows potential in skin cancer detection, but requires further clinical validation, particularly for diverse skin tones.
The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients experiencing increased skin cancer risk, highlighting the need for vigilant monitoring and innovative treatment strategies.
Advertisement
- Blood or Marrow Transplant Recipients Face Higher Skin Cancer Risk, Study Shows
Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal antibody, chronic graft-versus-host disease and post-transplant immunosuppression.Read more - AI Shows Promise in Skin Cancer Detection, But Clinical Validation Still Needed
Few studies in this analysis assessed the accuracy of AI in detecting melanoma in diverse skin tones.Read more - Protein Responsible for Parkinson’s Disease Also Drives Melanoma Progression
A new study suggests that targeting the protein alpha-synuclein could be a possible new target for treating melanoma.Read more - New Alpha Radiation Therapy Shows Promise for Hard-to-Treat Melanoma
Researchers said alpha particles are promising therapies that target cancer while minimizing the damage to nearby healthy tissues.Read more - Early Trial of Libtayo Combination Demonstrates Activity in Melanoma
Fianlimab plus Libtayo demonstrated persistent and significant clinical activity in patients with advanced melanoma.Read more
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement


















































